title: [Absence of bleeding recurrence of peptic ulcer after long term follow-up of successful eradication of Helicobacter pylori].
abstract: Helicobacter pylori (HP) eradication reduces dramatically the peptic ulcer relapse rate, but information regarding recurrence of peptic ulcer bleeding after eradication is still scanty. Available data show rebleeding rates of 0-3% per year in successfully eradication patients, compared with figures between 12 and 33% among the non eradicated ones. The aim of this study was to determine the rebleeding rate among successfully eradicated patients with a prior history of rebleeding peptic ulcer. 42 patients (34 male, mean age 49, range 18-74) hospitalised for Hp positive bleeding peptic ulcer undergoing conservative treatment, were given as soon as oral route was re-established, a one-week eradication treatment, followed by the same proton pump inhibitor for three or five weeks for duodenal and gastric ulcer healing respectively. No maintenance antiulcer therapy was indicated. Patients were advised not to take nonsteroideal anti-inflammatory drug. Ulcer healing and Hp eradication was confirmed in all 42 patients by means of endoscopy and biopsies for urease rapid test and histology four weeks after completion of the treatment. After this patients were invited to enter a long-term follow-up program with periodical visits. End point of the study was occurrence of rebleeding. Further endoscopies were planned when rebleeding or symptomatic relapse. Median follow-up time was 24.02 months, ranging from 3 up to 27 months. All patients were compliant with the follow-up visits. None of the patients presented with symptoms suggestive of ulcer relapse or upper gastrointestinal bleeding. Our data suggest, that Hp eradication can prevent bleeding relapses in patients with Hp positive bleeding peptic ulcers.
authors.affiliation: Servicio de Patología, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina.
authors.forename: M
authors.initials: M
authors.lastname: Amendola
authors.forename: R
authors.initials: R
authors.lastname: Farias
authors.forename: J
authors.initials: J
authors.lastname: Katz
authors.forename: P
authors.initials: P
authors.lastname: Luna
authors.forename: M
authors.initials: M
authors.lastname: Ianella
authors.forename: A
authors.initials: A
authors.lastname: Musi
authors.forename: L
authors.initials: L
authors.lastname: Boerr
authors.forename: J
authors.initials: J
authors.lastname: Valero
authors.forename: Z
authors.initials: Z
authors.lastname: Kogan
authors.forename: R
authors.initials: R
authors.lastname: Corti
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy* / Q000517:prevention & control; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents